<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0">
  <channel>
    <title>Best Of Week - Head &amp; Neck Cancer</title>
    <link>https://pubmed.ncbi.nlm.nih.gov</link>
    <description>Top 10 most impactful head and neck cancer papers this week, selected by AI</description>
    <lastBuildDate>Fri, 16 Jan 2026 07:02:38 +0000</lastBuildDate>
    <item>
      <title>#1 [90/100] Is proton therapy a new standard of care for oropharyngeal cancer?</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41519583/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41519583/</guid>
      <dc:creator>Jensen K, Grau C</dc:creator>
      <pubDate>Sat, 10 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;ðŸ”¥ CRITICAL - Score: 90/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; Published in a top-tier journal (Lancet) and addresses a critical clinical question regarding the standard of care for oropharyngeal cancer, potentially leading to significant changes in treatment protocols.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Jensen K, Grau C&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Lancet (London, England) | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1016/S0140-6736(25)02639-X'&gt;10.1016/S0140-6736(25)02639-X&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-10&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41519583/'&gt;41519583&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;i&gt;No abstract available&lt;/i&gt;</description>
    </item>
    <item>
      <title>#2 [78/100] Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41530380/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41530380/</guid>
      <dc:creator>Yap TA, Sweis RF, Vaishampayan U, Kilari D, Gainor JF, McKean M, Barve M, Tarhini AA, Bockorny B, Sonpavde G, et al.</dc:creator>
      <pubDate>Tue, 13 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;âœ¨ NOTABLE - Score: 78/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This phase 1 trial evaluates a first-in-class therapy in combination with pembrolizumab for immune checkpoint blockade-resistant tumors, indicating potential clinical relevance, although it lacks the definitive evidence of larger phase 3 trials.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Yap TA, Sweis RF, Vaishampayan U, Kilari D, Gainor JF, McKean M, Barve M, Tarhini AA, Bockorny B, Sonpavde G, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Nature medicine | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1038/s41591-025-04157-w'&gt;10.1038/s41591-025-04157-w&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-13&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41530380/'&gt;41530380&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;Although immune checkpoint inhibitor therapies have revolutionized oncology, many cancers are unresponsive or develop resistance that involves transforming growth factor-Î²1 (TGFÎ²1). This multicenter, open-label, phase 1 study (DRAGON trial, SRK-181-001) evaluated safety, pharmacokinetics, pharmacodynamics, predictive biomarkers and efficacy of linavonkibart, a first-in-class fully human selective anti-latent TGFÎ²1 antibody with anti-programmed cell death protein 1 (PD-1) therapy. The DRAGON trial was divided into three treatment parts: part A1 (dose-escalation cohorts with single-agent linavonkibart), part A2 (dose-escalation cohorts with the combination treatment of linavonkibart and pembrolizumab) and part B (dose-expansion cohorts with the combination treatment). The primary objective of the study was to determine the safety and tolerability of linavonkibart alone and in combination with pembrolizumab. Secondary objectives included evaluation of linavonkibart pharmacokinetics for each treatment paradigm, assessment of anti-linavonkibart antibody development (parts A and B) and measurement of antitumor activity (part B) after treatment. All primary and secondary objectives were met in the study. Overall, linavonkibart had a manageable safety profile, and combined therapy with pembrolizumab was generally consistent with that of pembrolizumab monotherapy. Dermatological reactions were the only additional risk identified. Neither cytokine release syndrome nor infusion interruption was observed in any patient enrolled in DRAGON. In part A (nâ€‰=â€‰34), no dose-limiting toxicities or grade 4 or 5 treatment-related adverse events occurred (linavonkibart; â‰¤3,000â€‰mg once every 3â€‰weeks (Q3W) and 2,000â€‰mg once every 2â€‰weeks (Q2W)). In part B (nâ€‰=â€‰78), patients progressing on prior anti-PD-1 therapy received linavonkibart (1,500â€‰mg Q3W/1,000â€‰mg Q2W) with pembrolizumab (200â€‰mg Q3W). This combination demonstrated confirmed objective response rates of 20.0%, 18.2%, 9.1% and 9.1% in anti-PD-1-resistant patients with clear cell renal cell cancer (ccRCC), melanoma, head and neck squamous cell cancer and urothelial cancer, respectively. Biomarker data provide proof of mechanism and a potential ccRCC patient selection strategy. ClinicalTrials.gov identifier: NCT04291079 .</description>
    </item>
    <item>
      <title>#3 [75/100] Smokeless Tobacco and Oral Cancer in Global Perspective.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41534101/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41534101/</guid>
      <dc:creator>Parascandola M, Nethan ST, Siddiqi K</dc:creator>
      <pubDate>Thu, 15 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;âœ¨ NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; The paper addresses the significant public health issue of smokeless tobacco and its link to oral cancer, published in a top-tier journal, which may influence clinical awareness and guidelines, though it does not present primary research data or novel therapeutic findings.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Parascandola M, Nethan ST, Siddiqi K&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; The New England journal of medicine | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1056/NEJMp2500631'&gt;10.1056/NEJMp2500631&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-15&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41534101/'&gt;41534101&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;i&gt;No abstract available&lt;/i&gt;</description>
    </item>
    <item>
      <title>#4 [75/100] Multi-center multi-omics integration predicts individualized prognosis in medullary thyroid carcinoma.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41535264/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41535264/</guid>
      <dc:creator>Zhou Y, Wang Y, Shi X, Wang J, Zang Z, Zhang L, Gui Z, Cai X, Hu P, Wang J, et al.</dc:creator>
      <pubDate>Wed, 14 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;âœ¨ NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study involves a large multi-center analysis with over 450 patients, providing novel insights into recurrence risk factors and molecular subtypes in medullary thyroid carcinoma, which could influence clinical management and risk stratification.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Zhou Y, Wang Y, Shi X, Wang J, Zang Z, Zhang L, Gui Z, Cai X, Hu P, Wang J, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Nature communications | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1038/s41467-025-67533-7'&gt;10.1038/s41467-025-67533-7&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-14&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41535264/'&gt;41535264&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;Medullary thyroid carcinoma (MTC) is a rare, aggressive neuroendocrine tumor with limited treatment options and frequent recurrence. Comprehensive recurrence risk stratification remains lacking. Here, we profile 482 MTC samples from 452 patients across ten Chinese clinical centers, identifying 10,092 proteins and mutations in 87.0% of patients. Clinically, MTC grading, concurrent papillary thyroid carcinoma, and lymph node metastasis are significant recurrence risk factors, whereas at the genetic level, RET M918T and RET S891A mutations are correlated with high recurrence risk in sporadic and hereditary MTC, respectively. Ubiquitinomics show downregulated E3 ligases CUL4B and TRIM32 are associated with structural recurrence. We define three molecular subtypes with distinct outcomes and present an integrative machine learning model combining clinical, genomic, and proteomic features, validated in an independent test dataset of 105 patients and a published dataset. This multi-center, multi-omics study enhances the understanding of MTC heterogeneity and facilitates personalized patient management.</description>
    </item>
    <item>
      <title>#5 [75/100] Incorporation of grade into stage in oral cavity squamous cell carcinoma: A novel staging schema.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41534318/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41534318/</guid>
      <dc:creator>Ho AS, Luu M, Manzoor D, Maluf H, Bailey C, Balzer B, Walgama ES, Jang JK, Scher KC, Moyers JT, et al.</dc:creator>
      <pubDate>Tue, 13 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;âœ¨ NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study involves a large retrospective analysis of over 46,000 cases, providing novel insights into the prognostic value of grade in oral cavity squamous cell carcinoma staging, which may influence clinical practice and treatment guidelines.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Ho AS, Luu M, Manzoor D, Maluf H, Bailey C, Balzer B, Walgama ES, Jang JK, Scher KC, Moyers JT, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Oral oncology | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1016/j.oraloncology.2025.107847'&gt;10.1016/j.oraloncology.2025.107847&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-13&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41534318/'&gt;41534318&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;BACKGROUND: While numerous cancer staging systems have incorporated grade into stage, the impact of grade on oral cavity carcinoma (OCC) prognosis has been conflicting. We investigated grade as a prognostic determinant in OCC staging. METHODS: Multivariable Cox regression models of OCC patients identified via U.S. cancer registry data were constructed to determine associations between grade (G1Â =Â low-grade, G2Â =Â intermediate-grade, G3Â =Â high-grade) and overall survival (OS). Recursive partitioning analysis (RPA) was used to derive staging schema. RESULTS: Overall, 46,789 OCC cases were identified across 1,222 institutions. On univariate analysis, higher grade was associated with worse 5-yr OS (G1: 73% [95% CI 72-74%], G2: 61% [95 CI 60-61%], G3: 49% [95% CI 48-51%] (pÂ &lt;Â 0.001). On multivariable analysis adjusting for other prognostic factors, these survival differences persisted. Compared to G1 tumors, both G2 (HR 1.25 [95% CI 1.19-1.30], pÂ &lt;Â 0.001) and G3 (HR 1.52 [95% CI 1.45-1.61], pÂ &lt;Â 0.001) tumors were associated with significantly worse OS. Similar results were seen when utilizing propensity score matching. RPA generated subgroups that mirrored AJCC8E, but with G3 cases performing worse for a given stage. A proposed TNMÂ +Â G staging schema was created with AJCC8E G3 cases upstaged by one category. Overall, 11.5% (4,745/36,623) cases were upstaged. TNMÂ +Â G performed better than AJCC8E by c-index (0.673 vs. 0.671) and Brier score (0.174 vs. 0.175). CONCLUSION: Large-scale analysis supports grade as an influential predictive determinant in OCC outcomes, with hazard on par with conventional staging factors. Incorporation of grade into stage strengthens existing AJCC OCC schema and pragmatically improves its ability to convey prognosis.</description>
    </item>
    <item>
      <title>#6 [75/100] Oncologic Outcomes of Transoral Robotic Surgery in HPV-Associated OPSCC: A Systematic Review and Meta-Analysis.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41521853/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41521853/</guid>
      <dc:creator>Cheung MH, Kim CH, Nguyen SA, Williamson L, Kejner A, Bobian M, Newman JG</dc:creator>
      <pubDate>Mon, 12 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;âœ¨ NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This systematic review and meta-analysis includes a substantial number of studies and a large patient cohort, providing important insights into oncologic outcomes of TORS for HPV-associated OPSCC, which may influence clinical practice and treatment guidelines.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Cheung MH, Kim CH, Nguyen SA, Williamson L, Kejner A, Bobian M, Newman JG&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1002/ohn.70101'&gt;10.1002/ohn.70101&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-12&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41521853/'&gt;41521853&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;OBJECTIVE: To define survival and recurrence outcomes of HPV associated oropharyngeal squamous cell carcinoma (OPSCC) following transoral robotic surgery (TORS). DATA SOURCES: PubMed, Scopus, CINAHL. REVIEW METHODS: A systematic review and meta-analysis were performed on studies employing TORS in HPV-associated OPSCC. Meta-analysis of continuous measures, proportions, and comparison of weighted proportion and relative risk were performed for patient characteristics and outcomes. RESULTS: A total of 58 studies, comprising 16,129 adults treated with TORS for OPSCC, were included. The mean age was 59.5 years (SD 2.08) (range 18-93), with an average follow-up of 43.4 months (SD 13.36); 83.5% of the cohort was male, and 85.6% had HPV-positive OPSCC. In the HPV-positive group, TORS survival rates were 91.0% at 1 year, 94.9% at 3 years, and 89.8% at 5 years. In comparison, the HPV-negative group had survival rates of 92.3%, 84.2%, and 72.9%, respectively. Significant survival differences were observed between cohorts at 3 and 5 years (Pâ€‰&lt;â€‰.0001). The HPV-positive group had a significantly higher likelihood of 5-year overall survival compared to the HPV-negative group (RRâ€‰=â€‰1.18, 95% CI: 1.05-1.34) Recurrence rates in HPV-positive patients were 2.0% local, 3.1% regional, and 5.3% locoregional, whereas HPV-negative patients had recurrence rates of 7.6% local, 6.0% regional, and 9.1% locoregional (Pâ€‰=â€‰.0037, .2143, .426, respectively). Distant metastasis rates were 5.6% in HPV-positive and 10.2% in HPV-negative patients (Pâ€‰=â€‰.0033). CONCLUSION: The higher survival rates and lower recurrences in HPV-positive OPSCC patients compared to their HPV-negative counterparts reflects the favorable long-term oncologic outcome seen in HPV-associated OPSCC.</description>
    </item>
    <item>
      <title>#7 [70/100] Stereotactic Body Radiation Therapy With Pembrolizumab in PD-1 Inhibitor Refractory, Recurrent or Metastatic, Head and Neck Squamous Cell Carcinoma: A Phase 2 Trial.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41520892/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41520892/</guid>
      <dc:creator>So J, Droznin A, Tiwari P, Chen YH, Chau N, Margalit DN, Tishler RB, Hanna GJ, Mak RH, Fitzgerald K, et al.</dc:creator>
      <pubDate>Fri, 09 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;âœ¨ NOTABLE - Score: 70/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This is a prospective phase 2 trial evaluating a novel combination of SBRT and pembrolizumab in a specific patient population with PD-1 inhibitor-refractory head and neck cancer, which may provide important insights into treatment options, although it lacks the robustness of a randomized controlled trial.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; So J, Droznin A, Tiwari P, Chen YH, Chau N, Margalit DN, Tishler RB, Hanna GJ, Mak RH, Fitzgerald K, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; International journal of radiation oncology, biology, physics | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1016/j.ijrobp.2025.12.043'&gt;10.1016/j.ijrobp.2025.12.043&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-09&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41520892/'&gt;41520892&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;PURPOSE: To evaluate the safety, feasibility, and clinical efficacy of stereotactic body radiation therapy (SBRT) combined with pembrolizumab in patients with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) who progressed on prior PD-1 inhibitor therapy. METHODS AND MATERIALS: This prospective, non-randomized phase II trial enrolled patients with PD-1 inhibitor-refractory R/M HNSCC. In Cohort A, a single lesion was treated with SBRT while other sites were left unirradiated. In Cohort B, all known oligometastatic lesions were treated with SBRT. Pembrolizumab was administered every 3 weeks in both cohorts. The primary endpoint was 3-month progression-free survival (PFS). Correlative immune analyses were performed on peripheral blood mononuclear cells using mass cytometry and TCRÎ² sequencing. RESULTS: Eighteen patients were treated (6 in Cohort A, 12 in Cohort B). Median PFS was 1.8 months in Cohort A and 5.7 months in Cohort B. The 3-month PFS rate was 17% (1/6) in Cohort A and 67% (8/12) in Cohort B, with an overall response rate of 25% (3/12) in Cohort B and no objective responses in Cohort A. Median OS was 7.6 months (95% CI: [0.7-32.9])in Cohort A and 10.1 months (95% CI: [5.8-49.7]) in Cohort B. In Cohort B there were 2 (2/12, 17%) Grade 4 toxicities observed in the setting of re-irradiation. Correlative studies showed that patients with PFS &gt;3 months had higher baseline frequencies of CD8+ central memory T cells and elevated CXCR5 expression on memory B cells. CONCLUSIONS: In anti PD-1-refractory R/M HNSCC, SBRT with pembrolizumab was safe and feasible, suggesting activity when all progressing lesions were treated. Immune profiling describes pre-existing memory T and B cell phenotypes that appear to correlate with treatment benefit. These findings support further study and clinical use of comprehensive SBRT plus PD-1 blockade in this hard-to-treat population.</description>
    </item>
    <item>
      <title>#8 [65/100] Comparative analysis of prevalences of sensorineural hearing loss from chemoradiotherapy versus radiotherapy in head and neck cancer patients: a systematic review and meta-analysis.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41535758/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41535758/</guid>
      <dc:creator>Bukuru J, Sibomana O</dc:creator>
      <pubDate>Wed, 14 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;ðŸ“Œ SELECTED - Score: 65/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This systematic review and meta-analysis provides important insights into the prevalence of sensorineural hearing loss in head and neck cancer patients treated with chemoradiotherapy versus radiotherapy, which could have clinical implications, but it does not present new clinical data or practice-changing findings.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Bukuru J, Sibomana O&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; BMC cancer | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1186/s12885-026-15551-z'&gt;10.1186/s12885-026-15551-z&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-14&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41535758/'&gt;41535758&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;INTRODUCTION: Head and neck cancer (HNC) is the seventh most prevalent cancer globally. Chemoradiotherapy (CRT) and radiotherapy (RT) are the two most common treatment modalities for HNC. However, both treatments are associated with adverse side effects, including hearing loss. This systematic review and meta-analysis aim to evaluate the pooled prevalence of sensorineural hearing loss (SNHL) among HNC patients undergoing CRT versus RT. METHODOLOGY: A comprehensive search of PubMed/MEDLINE, Google Scholar, DOAJ, AJOL, and the Cochrane Library was conducted using predefined key terms to identify original articles reporting the prevalence of SNHL in HNC patients treated with CRT or RT. Additionally, manual Google searches were performed to uncover relevant grey literature. The results were screened and included or excluded according to preset criteria. The Restricted Maximum Likelihood (REML) random-effects model was employed to calculate the overall pooled prevalence and separate prevalences in CRT and RT groups, as well as their respective heterogeneities, using Jamovi 2.3.28 software. Statistical significance was set at pâ€‰&lt;â€‰.05 for all analyses. RESULTS: The overall prevalence of SNHL among HNC patients treated with CRT or RT was 54.5% (95% CI: 44.9% -â€‰64.0%; IÂ² = 90.35%, pâ€‰&lt;â€‰.001). For CRT, the prevalence was 60.4% (95% CI: 50.5% -â€‰70.2%; IÂ² = 88.82%, pâ€‰&lt;â€‰.001). In contrast, the prevalence for RT was 32.9% (95% CI: 21.3% -â€‰44.4%; IÂ² = 60.15%, pâ€‰=â€‰.063). The risk of developing SNHL was nearly twice as high in patients treated with CRT compared to those treated with RT alone, with a prevalence ratio of 1.83. CONCLUSION: Both CRT and RT are associated with SNHL in HNC patients, with a significantly higher prevalence observed in those undergoing CRT compared to RT.</description>
    </item>
    <item>
      <title>#9 [65/100] Exploratory Biomarker Analysis of Abemaciclib in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma With Dysregulated CDK4/6 Pathway.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41527715/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41527715/</guid>
      <dc:creator>Park JH, Ahn HK, Kim HR, Kim S, Park KU, Yun T, Kim HJ, Lee SC, Cho SH, Park SG, et al.</dc:creator>
      <pubDate>Tue, 13 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;ðŸ“Œ SELECTED - Score: 65/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study presents an exploratory biomarker analysis within a clinical trial context, providing insights into the efficacy of abemaciclib in a specific patient population, but the small sample size and limited efficacy results suggest moderate impact rather than practice-changing findings.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Park JH, Ahn HK, Kim HR, Kim S, Park KU, Yun T, Kim HJ, Lee SC, Cho SH, Park SG, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Head &amp; neck | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1002/hed.70165'&gt;10.1002/hed.70165&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-13&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41527715/'&gt;41527715&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;BACKGROUND: HPV-negative HNSCC is driven by cell cycle dysregulation, including CDK4/6 activation. Abemaciclib targets this pathway and may offer therapeutic benefits. This study aimed to identify biomarkers predicting abemaciclib efficacy. METHODS: In the NGS-based TRIUMPH trial, patients with platinum-refractory HNSCC harboring CDK4/6 pathway alteration received abemaciclib, classified as "long stable disease (SD)" (progression-free survival [PFS] &gt;â€‰6â€‰months) and "short SD" (PFS &lt;â€‰6â€‰months). In this post hoc analysis, the genetic profiles were compared. InÂ vitro studies were conducted to assess abemaciclib's antitumor effects in HNSCC cell lines. RESULTS: Among 23 patients, abemaciclib showed limited efficacy (overall response rate, 0%; disease control rate, 43.5%). CDKN2A deletion was significantly associated with long SD (pâ€‰=â€‰0.0078), unlike CCND1 amplification and CDKN2A mutation. InÂ vitro, CDKN2A-deleted cell lines showed greater sensitivity to abemaciclib. CONCLUSIONS: Although abemaciclib resulted in limited tumor regression, CDKN2A deletion may be a predictive biomarker for prolonged disease stabilization. Further investigations on genomically selected populations and combination strategies are required.</description>
    </item>
    <item>
      <title>#10 [65/100] Prognostic significance of p16 and immune cell infiltration in recurrent/metastatic head and neck squamous cell carcinoma treated with PD-1 inhibition: a national DAHANCA cohort study.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41529587/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41529587/</guid>
      <dc:creator>SÃ¸by S, Mortensen D, Gothelf A, Gyldenkerne N, Maare C, Lonkvist CK, Andersen M, Kjeldsen R, Toustrup K, Tramm T, et al.</dc:creator>
      <pubDate>Mon, 12 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;ðŸ“Œ SELECTED - Score: 65/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study is a large retrospective cohort analysis from a national database, focusing on prognostic biomarkers in a relevant clinical context of PD-1 inhibition for head and neck cancer, but lacks the robustness of a randomized controlled trial or prospective design.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; SÃ¸by S, Mortensen D, Gothelf A, Gyldenkerne N, Maare C, Lonkvist CK, Andersen M, Kjeldsen R, Toustrup K, Tramm T, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Oral oncology | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1016/j.oraloncology.2026.107849'&gt;10.1016/j.oraloncology.2026.107849&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-12&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41529587/'&gt;41529587&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;PD-1 inhibition has become an established treatment option for recurrent/metastatic head and neck squamous cell carcinoma (rmHNSCC). However, there is a clear need for improved prognostic tools. This study aimed to identify immune-related tissue biomarkers associated with overall survival (OS) or progression-free survival (PFS) in patients treated with PD-1 inhibition. This national real-world phase IV multicenter retrospective cohort study included Danish patients treated between 2017 and 2023. Pre-treatment biopsies were collected for immunohistochemical analyses. All patients were PD-L1 positive with histologically confirmed rmHNSCC treated with pembrolizumab or nivolumab monotherapy. Biomarker expression was assessed for CD4, CD8, FOXP3, CD20, CD66b, CD68, STING, cGAS, and tumor-infiltrating lymphocytes (TILs), using the median expression as the cut-off value. Formalin-fixed, paraffin-embedded tumor tissue was obtained from 263 eligible patients. Concurrent above median levels of FOXP3 and CD68 were associated with a lower risk of progression (HRPFS: 0.47 [95Â % CI: 0.33-0.67]). This interaction appeared to be driven by p16+ oropharyngeal cancers (OPC), where patients with concurrent above median levels of FOXP3 and CD68 showed a median 2-year PFS of 68Â % [95Â % CI: 42-86] in contrast to those with one or none of the two markers above the median level with a 2-year PFS of 3Â % [95Â % CI: 0-12] (pÂ &lt;Â 0.001). In this real-world cohort, a subgroup with a promising prognosis was identified. This subgroup was characterized by p16+ OPC along with concurrent above median levels of FOXP3 and CD68. PD-L1 alone showed no significant association with outcomes.</description>
    </item>
  </channel>
</rss>
